EVOK (Evoke Pharma) Accounts Payable & Accrued Expense : $4.18 Mil (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Accounts Payable & Accrued Expense?

Evoke Pharma's quarterly accounts payable & accrued expense increased from Mar. 2024 ($3.69 Mil) to Jun. 2024 ($4.05 Mil) and increased from Jun. 2024 ($4.05 Mil) to Sep. 2024 ($4.18 Mil).

Evoke Pharma's annual accounts payable & accrued expense increased from Dec. 2021 ($0.87 Mil) to Dec. 2022 ($0.93 Mil) and increased from Dec. 2022 ($0.93 Mil) to Dec. 2023 ($3.32 Mil).

Evoke Pharma Accounts Payable & Accrued Expense Historical Data

The historical data trend for Evoke Pharma's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Accounts Payable & Accrued Expense Chart

Evoke Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.03

6.27

0.87

0.93

3.32

Evoke Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.40	3.32	3.69	4.05	4.18

Evoke Pharma Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Evoke Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Stevens Avenue, Suite 230, Solana Beach, CA, USA, 92075

Website

https://www.evokepharma.com

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Executives

Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio	officer: Exec VP, Chief Bus. Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder	director, 10 percent owner	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah	10 percent owner	12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson	officer: Chief Medical Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady	director	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn	director
Lvpmc, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p.	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111